What Caligan Partners LP reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 1727492 · Filed Aug 14, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 2M |
| +18.7% |
| $367.4M |
| 17.3% |
ABVXAbivax S.A. | 1.6M | +6.6% | $207.6M | 9.8% |
PCVXVaxcyte, Inc. | 2.2M | +6.2% | $127.2M | 6% |
EXELExelixis, Inc. | 1.6M | ±0% | $84.5M | 4% |
TNGXTango Therapeutics, Inc. | 2.5M | +3.8% | $78.2M | 3.7% |
AVTXAvalo Therapeutics, Inc. | 3.2M | +93.5% | $58.5M | 2.8% |
XENEXenon Pharmaceuticals Inc. | 889.9K | −36.1% | $53.7M | 2.5% |
ADMAAdma Biologics, Inc. | 5.7M | +20.4% | $47.9M | 2.3% |
| 251.8K | +10.0% | $47.2M | 2.2% |
LBRXLB Pharmaceuticals Inc | 1.4M | ±0% | $46.7M | 2.2% |
IMCRImmunocore Holdings plc | 1.4M | New | $43.9M | 2.1% |
VRDNViridian Therapeutics, Inc. | 2.2M | New | $40.3M | 1.9% |
VORVor Biopharma Inc. | 1.9M | ±0% | $35.4M | 1.7% |
SABSSAB Biotherapeutics, Inc. | 8M | ±0% | $31.1M | 1.5% |
IVAInventiva S.A. | 8.2M | +64.1% | $30.9M | 1.5% |
AURAAura Biosciences, Inc. | 4.3M | +1,769.9% | $30.5M | 1.4% |
TYRATyra Biosciences, Inc. | 807K | −36.8% | $25.8M | 1.2% |
IRDOpus Genetics, Inc. | 6.1M | +0.0% | $25M | 1.2% |
ANIKAnika Therapeutics, Inc. | 1.4M | ±0% | $21M | 1% |
SGMTSagimet Biosciences Inc. | 2.5M | New | $19.3M | 0.9% |
ARTVArtiva Biotherapeutics, Inc. | 1.7M | New | $16.8M | 0.8% |
FTHFaeth Therapeutics, Inc. | 629.5K | +399.6% | $15.7M | 0.7% |
MBXMBX Biosciences, Inc. | 200K | −76.4% | $11M | 0.5% |
VRCAVerrica Pharmaceuticals Inc. | 923.9K | ±0% | $5.7M | 0.3% |
| 90K | ±0% | $3.3M | 0.2% |
| 300K | ±0% | $2.5M | 0.1% |
CLRBCellectar Biosciences, Inc. | 470K | New | $1.3M | 0.1% |
